PerkinElmer, Inc. (PKI) and Oxford Immunotec Global PLC (OXFD) have reached an agreement on terms under which PerkinElmer will acquire Oxford Immunotec. Oxford shareholders will be entitled to receive $22.00 in cash for each outstanding ordinary share. This value the company's entire issued and to be issued ordinary share capital at approximately $591 million.

Create Account

Dark

chart

exchange

Check out our Level2View

PerkinElmer, Inc. (PKI) and Oxford Immunotec Global PLC (OXFD) have reached an agreement on terms under which PerkinElmer will acquire Oxford Immunotec. Oxford shareholders will be entitled to receive $22.00 in cash for each outstanding ordinary share. This value the company's entire issued and to be issued ordinary share capital at approximately $591 million.

RTTNews | Jan 7, 2021 07:16AM EST

07:15 Thursday, January 7, 2021 (RTTNews.com) - PerkinElmer, Inc. (PKI) and Oxford Immunotec Global PLC (OXFD) have reached an agreement on terms under which PerkinElmer will acquire Oxford Immunotec. Oxford shareholders will be entitled to receive $22.00 in cash for each outstanding ordinary share. This value the company's entire issued and to be issued ordinary share capital at approximately $591 million.

Headquartered in Abingdon, UK, Oxford Immunotec is recognized as a global leader of proprietary test kits for latent tuberculosis.

PerkinElmer anticipates the deal to be modestly accretive to non-GAAP earnings in year-one following the close.

Read the original article on RTTNews ( https://www.rttnews.com/3158451/perkinelmer-to-acquire-oxford-immunotec-quick-facts.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved